Interview with CEO of SilkTech Biopharmaceuticals, Brian Lawrence, PhD
Clinical Stage
2021-04-19T22:50:35.000Z
SilkTech Biopharmaceuticals is Minneapolis based biotech company developing silk-based anti-inflammatory biotherapeutics. Currently, its lead drug candidate, Amlisimod (SDP-4) is in Phase 2 clinical trial for Dry Eye Disease.